FAPI-74 PET/CT using either 18F-AlF or cold-kit 68Ga labeling

• Verfasst von: Giesel, Frederik L. [VerfasserIn]
• Verfasst von: Adeberg, Sebastian [VerfasserIn]
• Verfasst von: Syed, Mustafa [VerfasserIn]
• Verfasst von: Lindner, Thomas [VerfasserIn]
• Verfasst von: Jiménez Franco, Luis David [VerfasserIn]
• Verfasst von: Mavriopoulou, Eleni [VerfasserIn]
• Verfasst von: Staudinger, Fabian [VerfasserIn]
• Verfasst von: Tonndorf-Martini, Eric [VerfasserIn]
• Verfasst von: Regnery, Sebastian [VerfasserIn]
• Verfasst von: Rieken, Stefan [VerfasserIn]
• Verfasst von: El-Shafie, Rami [VerfasserIn]
• Verfasst von: Röhrich, Manuel [VerfasserIn]
• Verfasst von: Flechsig, Paul [VerfasserIn]
• Verfasst von: Kluge, Andreas [VerfasserIn]
• Verfasst von: Altmann, Annette [VerfasserIn]
• Verfasst von: Debus, Jürgen [VerfasserIn]
• Verfasst von: Haberkorn, Uwe [VerfasserIn]
• Verfasst von: Kratochwil, Clemens [VerfasserIn]
• Titel: FAPI-74 PET/CT using either 18F-AlF or cold-kit 68Ga labeling
• Titelzusatz: biodistribution, radiation Dosimetry, and tumor delineation in lung cancer patients
• Verf.angabe: Frederik L. Giesel, Sebastian Adeberg, Mustafa Syed, Thomas Lindner, Luis David Jiménez-Franco, Eleni Mavriopoulou, Fabian Staudinger, Eric Tonndorf-Martini, Sebastian Regnery, Stefan Rieken, Rami El Shafie, Manuel Röhrich, Paul Flechsig, Andreas Kluge, Annette Altmann, Jürgen Debus, Uwe Haberkorn, Clemens Kratochwil
• E-Jahr: 2021
• Jahr: February 1, 2021
• Umfang: 7 S.
• Fussnoten: Im Titel sind die Zahlen 18 und 68 hochgestellt ; Gesehen am 12.10.2021
• Titel Quelle: Enthalten in: Journal of nuclear medicine
• Ort Quelle: New York, NY : Soc., 1964
• Jahr Quelle: 2021
• Band/Heft Quelle: 62(2021), 2, Seite 201-207
• ISSN Quelle: 2159-662X
• ISSN Quelle: 1535-5667
• DOI: doi:10.2967/jnumed.120.245084
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: cancer-associated fibroblasts
• Sach-SW: cold kit
• Sach-SW: FAPI PET/CT
• Sach-SW: lung cancer
• Sach-SW: radiation dosimetry
• K10plus-PPN: 1773408615

Abstract

68Ga-fibroblast activation protein inhibitors (FAPIs) 2, 4, and 46 have already been proposed as promising PET tracers. However, the short half-life of 68Ga (68 min) creates problems with manufacture and delivery. 18F (half-life, 110 min) labeling would result in a more practical large-scale production, and a cold-kit formulation would improve the spontaneous availability. The NOTA chelator ligand FAPI-74 can be labeled with both 18F-AlF and 68Ga. Here, we describe the in vivo evaluation of 18F-FAPI-74 and a proof of mechanism for 68Ga-FAPI-74 labeled at ambient temperature. Methods: In 10 patients with lung cancer, PET scans were acquired at 10 min, 1 h, and 3 h after administration of 259 ± 26 MBq of 18F-FAPI-74. Physiologic biodistribution and tumor uptake were semiquantitatively evaluated on the basis of SUV at each time point. Absorbed doses were evaluated using OLINDA/EXM, version 1.1, and QDOSE dosimetry software with the dose calculator IDAC-Dose, version 2.1. Identical methods were used to evaluate one examination after injection of 263 MBq of 68Ga-FAPI-74. Results: The highest contrast was achieved in primary tumors, lymph nodes, and distant metastases at 1 h after injection, with an SUVmax of more than 10. The effective dose per a 100-MBq administered activity of 18F-FAPI-74 was 1.4 ± 0.2 mSv, and for 68Ga-FAPI-74 it was 1.6 mSv. Thus, the radiation burden of a diagnostic 18F-FAPI-74 PET scan is even lower than that of PET scans with 18F-FDG and other 18F tracers; 68Ga-FAPI-74 is comparable to other 68Ga ligands. FAPI PET/CT supported target volume definition for guiding radiotherapy. Conclusion: The high contrast and low radiation burden of FAPI-74 PET/CT favor multiple clinical applications. Centralized large-scale production of 18F-FAPI-74 or decentralized cold-kit labeling of 68Ga-FAPI-74 allows flexible routine use.